高级搜索

重组人红细胞生成素治疗恶性肿瘤贫血的临床观察

程 晶, 伍 钢, 彭 纲, 黄 晶

程 晶, 伍 钢, 彭 纲, 黄 晶. 重组人红细胞生成素治疗恶性肿瘤贫血的临床观察[J]. 肿瘤防治研究, 2005, 32(08): 511-512. DOI: 10.3971/j.issn.1000-8578.1276
引用本文: 程 晶, 伍 钢, 彭 纲, 黄 晶. 重组人红细胞生成素治疗恶性肿瘤贫血的临床观察[J]. 肿瘤防治研究, 2005, 32(08): 511-512. DOI: 10.3971/j.issn.1000-8578.1276
CHENG Jing, WU Gang, PENG Gang, HUANG Jing. Clinical Observation of Erythropoietin in Treating the Malignant Tumour Anemia[J]. Cancer Research on Prevention and Treatment, 2005, 32(08): 511-512. DOI: 10.3971/j.issn.1000-8578.1276
Citation: CHENG Jing, WU Gang, PENG Gang, HUANG Jing. Clinical Observation of Erythropoietin in Treating the Malignant Tumour Anemia[J]. Cancer Research on Prevention and Treatment, 2005, 32(08): 511-512. DOI: 10.3971/j.issn.1000-8578.1276

重组人红细胞生成素治疗恶性肿瘤贫血的临床观察

详细信息
    通讯作者:

    程 晶

  • 中图分类号: R973 + . 3

Clinical Observation of Erythropoietin in Treating the Malignant Tumour Anemia

More Information
    Corresponding author:

    CHENG Jing

  • 摘要: 目的 观察重组人红细胞生成素(rHuEpo)治疗恶性肿瘤贫(MTA)的效果。方法 治疗组患者接受rHuEpo皮下注射,10000)U,隔日1次,疗程8周。疗效不明显或有缺铁实验室证据的患者加用琥珀酸亚铁0.1g口服,每日3次。治疗中如患者血红蛋白≤80g/L,可考虑给予输血。对照组不给予rHuEpo,其他同治疗组。结果 治疗组有22例(73.3%)血红蛋白上升〉20g/L,对照组仅4例(13.3%)血红蛋白上升〉20g/L,两组有效率差异有统计学意义(P〈0.01)。结论 rHuEpo治疗MTA安全有效。

     

    Abstract: Objective  To observe the effect of recombinant human erythropietin ( rHuEpo) in t reating malignant tumour anemia (MTA) . Methods  Thirty cases of treated group were treated with rHuEpo 10000 U, qod, lasted for 8 weeks . Thirty cases of control group were treated with support cares and the blood transfusion. Results  The overall response rates of treated and control group were 73. 3 %(22/30) and 13. 3 % (4/ 30) respectively, and the increased Hb of treated group is more higher than that of control group ( P < 0. 01) . Conclusion  rHuEpo is effective and safe in treating MTA.

     

计量
  • 文章访问数:  1794
  • HTML全文浏览量:  18
  • PDF下载量:  645
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-09-12
  • 修回日期:  2005-02-20
  • 刊出日期:  2005-08-04

目录

    /

    返回文章
    返回
    x 关闭 永久关闭